Definition & Epidemiology
Tuberous sclerosis complex (TSC; OMIM #191100, #613254) is a rare autosomal dominant neurocutaneous phakomatosis characterized by the development of benign hamartomas in multiple organ systems. It affects ~1 in 6,000–10,000 live births, with equal gender and racial distribution. Approximately two-thirds of cases result from de novo mutations; the remainder are inherited. Penetrance is near-complete by adulthood, but expressivity is highly variable—even among affected family members—due to modifier genes, epigenetic factors, and somatic mosaicism.
Genetics & Pathophysiology
TSC is caused by loss-of-function mutations in either:
- TSC1 (9q34): encodes hamartin,
- TSC2 (16p13.3): encodes tuberin.
Hamartin and tuberin form a stable heterodimeric complex that acts as a critical negative regulator of the mTOR signaling pathway—a master controller of cell growth, proliferation, metabolism, and autophagy. Inactivation of either gene leads to constitutive mTORC1 activation, resulting in aberrant cellular growth and hamartoma formation.
- Genotype–phenotype correlations:
- TSC2 mutations are generally associated with a more severe phenotype than TSC1, including earlier seizure onset, higher risk of intellectual disability (ID), larger renal angiomyolipomas, and increased likelihood of cortical tubers.
- Large TSC2 deletions (including contiguous PKD1 gene) predispose to early-onset polycystic kidney disease.
- Mosaic TSC may present with milder or atypical features and can complicate genetic counseling.
Source: Northrup S, et al. Tuberous Sclerosis Complex Diagnostic Criteria Update: 2012. Neurology. 2013;81(5):411–418.
Multisystem Clinical Manifestations (Current Diagnostic Framework)
The 2012 International TSC Consensus Conference revised diagnostic criteria, distinguishing between definite, possible, and suspected TSC using major and minor features. Genetic confirmation (pathogenic TSC1/TSC2 variant) is sufficient for a definitive diagnosis.
Neurological Manifestations (Leading cause of morbidity)
| Feature | Prevalence | Clinical Significance |
|---|---|---|
| Cortical tubers | ~90% | Focal dysplastic lesions; number/location correlate with seizure severity and cognitive outcomes. MRI: T2/FLAIR hyperintense, subependymal nodules (SENs) often calcified. |
| Subependymal giant cell astrocytoma (SEGA) | 10–20%, typically ages 4–25 | Arises near foramen of Monro; can cause obstructive hydrocephalus. Requires serial neuroimaging (MRI q6–12mo in children). |
| Epilepsy | 80–90% | Infantile spasms (IS) occur in ~30–40% of infants—often the first manifestation. Focal seizures also common. Early control is critical: uncontrolled IS → higher risk of developmental regression and Lennox-Gastaut syndrome. |
| TSC-Associated Neuropsychiatric Disorders (TAND) | >90% | Spectrum includes intellectual disability (IQ <70 in ~50%), autism spectrum disorder (~40–50%), ADHD, anxiety, self-injury, and aggression. TAND is now recognized as a core diagnostic category per consensus guidelines. |
Key Insight: EEG should be obtained in all infants with suspected TSC—even without clinical seizures—as subclinical epileptiform activity predicts later epilepsy.
Dermatologic Features (Often Earliest Clues)
| Feature | Sensitivity | Clinical Utility |
|---|---|---|
| Hypomelanotic macules (“ash-leaf spots”) | >95% (by age 1) | Best visualized under Wood’s lamp; may be present at birth. First sign in many infants. |
| Facial angiofibromas | ~75–85% | Appear ages 2–5 years; can cause psychosocial distress. |
| Shagreen patch | ~20–30% | Connective tissue nevus over lumbar sacrum; pathognomonic. |
| Ungual fibromas | ~20% (more common in adults) | Periungual or subungual; tender, cause nail deformity. |
Cardiac
- Rhabdomyomas: Present in ~50–70% of infants; often multiple and bilateral.
- Most regress spontaneously by adolescence.
- Neonatal presentation: arrhythmias (supraventricular tachycardia), outflow obstruction, or heart failure.
Note: Prenatal ultrasound may detect large/multiple rhabdomyomas; fetal echo recommended if suspicion is high.
Renal (Major cause of mortality in adults)
| Lesion | Prevalence (by age 30) | Risks & Management |
|---|---|---|
| Angiomyolipoma (AML) | ~70–80% | Risk of life-threatening hemorrhage if >3 cm; mTOR inhibitors (sirolimus/everolimus) shrink tumors and reduce bleeding risk. Guidelines recommend baseline renal MRI/CT and annual monitoring. |
| Renal cysts | ~20–30% (higher with TSC2/PKD1 deletions) | May progress to renal failure; monitor eGFR annually. |
Pulmonary
- Lymphangioleiomyomatosis (LAM):
- Occurs in up to 40% of adult women (rare in men/children).
- Presents with dyspnea, pneumothorax, chylous effusions.
- Diagnosis: HRCT showing diffuse cystic lung changes; confirm with VEGF-D >800 pg/mL (specificity >90%).
- Management: mTOR inhibitors (everolimus) stabilize lung function (MILES trial). Avoid estrogen-containing therapies.
Ocular
- Retinal hamartomas:
- Astrocytic; can be nodular (“phakoma”) or mulberry-type.
- Usually asymptomatic but may impair vision if macula involved.
- Fundus exam + OCT recommended annually in children.
Diagnostic Workup (Per Current Guidelines)
- Genetic Testing (First-tier):
- TSC1/TSC2 sequencing + deletion/duplication analysis (MLPA or array-CGH).
- Sensitivity: ~85–90% in definite TSC; lower in mosaic cases (~50–75%).
- Action: If negative but high clinical suspicion, consider RNA sequencing or methylation analysis.
- Baseline Multisystem Evaluation (Per 2012 Consensus & TSC International Registry Recommendations):SystemTestFrequencyBrainMRI (with contrast for SEGA)Baseline + q1–3y in children; q3–5y adults unless new symptomsKidneysMRI preferred (avoid CT radiation)Baseline + annual MRI q2–3y if AML >3 cm or growingLungs (adult women)HRCT ± VEGF-DBaseline at age 18–25; repeat every 5–10y unless symptomsHeart (infants)EchocardiogramAt diagnosis; if rhabdomyomas present, q6mo until regressionEyesDilated fundus exam + OCTAnnually in children
- Neuropsychiatric Assessment:
- Formal TAND screening tool (e.g., TAND checklist) at least annually—identifies needs not captured in routine visits.
Management: Evidence-Based Approaches
Epilepsy
- First-line: Vigabatrin for infantile spasms (FDA-approved; 60–70% cessation rate if started early).
- Other ASMs: Topiramate, valproate, levetiracetam. Ketogenic diet shows ~50% ≥50% seizure reduction in refractory cases.
- Surgical: Epileptiform focus resection or hemispherotomy for drug-resistant focal epilepsy. SEGA-related hydrocephalus may require endoscopic resection or shunting.
SEGA
- mTOR inhibitors (everolimus): First-line for growing SEGAs (EVIVE trial). Dose: target trough 5–10 ng/mL. Avoid surgery if feasible.
- Monitoring: MRI q3mo during treatment, then q6–12mo.
Renal AML
- mTOR inhibitors: Everolimus or sirolimus for AML >3 cm (SIRENA trial). Shrinkage by ≥50% in >80%.
- Embolization: For acute hemorrhage or preoperative planning.
- Nephron-sparing surgery if mTOR contraindicated.
LAM
- Everolimus: First-line (MILES trial: 53% vs. 16% placebo achieved ≥20 mL improvement in FEV₁).
- Supportive: Pulmonary rehab, pneumothorax management, avoid smoking/estrogen.
Dermatologic & Psychiatric
- Facial angiofibromas: Topical sirolimus (off-label; Level B evidence), laser therapy (PDL).
- TAND: Multimodal—behavioral therapy, CBT, SSRIs for anxiety/depression. Early educational intervention critical.
Genetic Counseling & Reproductive Options
- 50% transmission risk to offspring.
- Prenatal testing: CVS/amniocentesis if familial mutation known; fetal US for cardiac rhabdomyomas.
- Preimplantation genetic diagnosis (PGD) available.
Prognosis & Mortality
- Life expectancy reduced by ~10–20 years vs. general population.
- Leading causes of death:
- Children: Status epilepticus, SUDEP, cardiac rhabdomyoma complications.
- Adults: Renal failure (AML hemorrhage), LAM respiratory failure, CNS tumors.
- Mortality risk factors: Early-onset intractable epilepsy, TSC2 mutations, intellectual disability > moderate severity.
Key Takeaways for Clinicians
- TSC is a systemic mTORopathy—early diagnosis enables proactive surveillance.
- Seizures and TAND are underrecognized drivers of disability; screen annually with validated tools.
- mTOR inhibitors (everolimus/sirolimus) have transformed management of SEGAs, AML, and LAM.
- Multidisciplinary clinics improve outcomes—ideal team includes neurologist, nephrologist, pulmonologist, geneticist, psychiatrist, and social work.
Sources:
- European Tuberous Sclerosis Expert Consensus (2021), Lancet Neurol.
- TSC International Diagnostic Criteria Update (2012), Neurology.
- Everolimus Extended-Release Tablets (Afinitor®) FDA Label.
- TACERN Consortium Guidelines for Renal and Pulmonary Management.
Note: Clinical trial data continue to evolve—refer to clinicaltrials.gov (e.g., NCT05195367 assessing new mTOR inhibitors in TSC).
